Anne Vincent-Salomon

Summary

Affiliation: Institut Curie
Country: France

Publications

  1. doi request reprint Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma?
    Isabelle de Mascarel
    J Clin Oncol 26:4514-5; author reply 4515. 2008
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
  3. doi request reprint High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Breast 21:380-3. 2012
  4. pmc Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
    Kevin C H Ha
    Department of Human Genetics, McGill University, Montreal, Quebec, H3A 1B1, Canada
    BMC Med Genomics 4:75. 2011
  5. ncbi request reprint [Columnar lesions: a frequent diagnosis in breast pathology!]
    Anne Vincent-Salomon
    Departement de Pathologie, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 5
    Ann Pathol 23:593-6. 2003
  6. pmc Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris Cedex 05, France
    Breast Cancer Res 9:R24. 2007
  7. pmc Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
    A Vincent-Salomon
    Institut Curie, Paris, France
    J Clin Pathol 61:570-6. 2008
  8. ncbi request reprint Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study
    A Vincent-Salomon
    Institut Curie, Paris, France
    Histopathology 42:337-47. 2003
  9. pmc HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
    A Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris, France
    Br J Cancer 96:654-9. 2007
  10. ncbi request reprint Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Unité Mixte de Recherche 144 Centre National de la Recherche Scientifique, Paris, France
    Clin Cancer Res 10:1392-400. 2004

Detail Information

Publications88

  1. doi request reprint Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma?
    Isabelle de Mascarel
    J Clin Oncol 26:4514-5; author reply 4515. 2008
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
    ....
  3. doi request reprint High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Breast 21:380-3. 2012
    ..Our aim was to evaluate the risk of relapse for lobular carcinoma in situ (LCIS) patients, diagnosed on mammography performed for microcalcifications and according to proliferation assessed by Ki67 staining...
  4. pmc Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
    Kevin C H Ha
    Department of Human Genetics, McGill University, Montreal, Quebec, H3A 1B1, Canada
    BMC Med Genomics 4:75. 2011
    ..We sought to identify putative gene fusions in the transcriptomes of these cancers using high-throughput RNA sequencing (RNA-Seq)...
  5. ncbi request reprint [Columnar lesions: a frequent diagnosis in breast pathology!]
    Anne Vincent-Salomon
    Departement de Pathologie, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 5
    Ann Pathol 23:593-6. 2003
    ..When architectural atypia is associated, a careful search for atypical ductal hyperplasia or for low grade DCIS needs to be performed, especially on vacuum assisted macrobiopsies for an appropriate management of the patient...
  6. pmc Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris Cedex 05, France
    Breast Cancer Res 9:R24. 2007
    ..The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC)...
  7. pmc Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
    A Vincent-Salomon
    Institut Curie, Paris, France
    J Clin Pathol 61:570-6. 2008
    ..Finally, this review addresses the main biological questions raised by disseminated tumour cells, in particular understanding tumour dormancy and identifying metastatic stem cells...
  8. ncbi request reprint Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study
    A Vincent-Salomon
    Institut Curie, Paris, France
    Histopathology 42:337-47. 2003
    ..This prompted us to perform a multicentric IHC calibration test to achieve a maximum accuracy of HER2-IHC compared with HER2-FISH taken as the reference method...
  9. pmc HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
    A Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris, France
    Br J Cancer 96:654-9. 2007
    ..Therefore, the efficiency of anti-HER2 adjuvant therapy could be evaluated, in a clinical trial, by sequential detection of HER2-positive micrometastatic cells within the bone marrow, before and after treatment...
  10. ncbi request reprint Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Unité Mixte de Recherche 144 Centre National de la Recherche Scientifique, Paris, France
    Clin Cancer Res 10:1392-400. 2004
    ....
  11. doi request reprint Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast
    Anne Vincent-Salomon
    Institut Curie, Department of Tumor Biology, Paris, France
    Clin Cancer Res 14:1956-65. 2008
    ..To gain insight into genomic and transcriptomic subtypes of ductal carcinomas in situ of the breast (DCIS)...
  12. ncbi request reprint Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Int J Cancer 114:291-8. 2005
    ..A larger study would be useful to confirm the importance of uPAR to define higher risk subgroups of breast cancer patients with micrometastatic disease...
  13. ncbi request reprint Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first
    Marc A Bollet
    Department of Radiation Oncology, Institut Curie, Paris, France
    Radiother Oncol 82:272-80. 2007
    ....
  14. doi request reprint A prognostic DNA signature for T1T2 node-negative breast cancer patients
    Eleonore Gravier
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, Paris, France
    Genes Chromosomes Cancer 49:1125-34. 2010
    ..34; 95% confidence interval 1.01-11.02; P = 4.78 × 10(-2), Wald test). This study shows that tumor DNA contains important prognostic information that may help to predict metastasis in T1T2N0 tumors of the breast...
  15. doi request reprint Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, Paris, France
    Clin Cancer Res 14:3306-11. 2008
    ..Clinical significance of disseminated tumor cells (DTC) in bone marrow of early breast cancer patients has been reported, but improvements in detection methods are needed...
  16. ncbi request reprint Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, 75005 Paris Cedex, France
    Eur J Cancer 45:1979-86. 2009
    ....
  17. doi request reprint Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer
    Christophe Le Tourneau
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Clin Oncol 35:242-6. 2012
    ....
  18. pmc The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 6:e20297. 2011
    ..The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy...
  19. pmc Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma
    Fabien Reyal
    Departement de Chirurgie, Institut Curie, Paris, France
    PLoS ONE 7:e35184. 2012
    ..Since most of the genes included in the GG are involved in cell proliferation, we performed a retrospective study to compare the prognostic value of GG, Mitotic Index and Ki67 score...
  20. ncbi request reprint Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors
    Jérôme Meunier
    Department of Clinical Hematology, Institut Curie, Paris, France
    Leuk Lymphoma 47:1295-305. 2006
    ..Our patient cohort represents one of the largest published series defining the characteristics and prognostic factors of primary conjunctival low-grade malignant lymphoma...
  21. ncbi request reprint Histological margin assessment for breast ductal carcinoma in situ: precision and implications
    Brigitte Sigal-Zafrani
    Department of Pathology, Institut Curie, 26 Rue d Ulm, 75248 Paris, France
    Mod Pathol 17:81-8. 2004
    ..A standard for margin status reporting and pathological processing of screen-detected DCIS in situ lesions will help in the interpretation of data from different institutions...
  22. pmc Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 8:e55901. 2013
    ..The present study aims to validate Ki67 as prognostic factor in a large cohort of early-stage (pT1-pT2, pN0) breast cancer patients...
  23. ncbi request reprint Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer
    Isabelle Bernard-Pierrot
    UMR 144, Centre National de la Recherche Scientifique, Institut Curie, Paris, France
    Cancer Res 68:7165-75. 2008
    ..PPAPDC1B may also potentiate the estrogen receptor pathway by down-regulating DUSP22...
  24. ncbi request reprint High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice
    Didier Decaudin
    Department of Clinical Hematology, Section de Recherche, Institut Curie, Paris, France
    Anticancer Drugs 17:685-95. 2006
    ..This result therefore indicates that combined rituximab and gemcitabine could be an alternative approach in patients with posttransplant lymphoproliferative disease...
  25. doi request reprint Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma
    Nadège Gruel
    Institut Curie, Translational Research Department, Paris, France
    Eur J Cancer 46:2399-407. 2010
    ..These molecular specificities should help with the identification of new therapeutic targets for ILC patients...
  26. pmc Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris, France INSERM U830, Institut Curie, Paris, France
    PLoS ONE 8:e76496. 2013
    ..The accurate prognosis definition to tailor treatment for early luminal invasive breast carcinoma patients remains challenging...
  27. pmc TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer
    Virginie Maire
    Institut Curie, Research Center, Paris, France Breast Cancer Biology Group, Department of Translational Research, Paris, France
    PLoS ONE 8:e63712. 2013
    ..These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis associated subgroup of breast cancer...
  28. doi request reprint Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas
    Nicolas Pécuchet
    Institut Curie, Centre de Recherche, Paris, France INSERM U830, Paris, France Department of Tumor Biology, Institut Curie, Paris, France
    Int J Cancer 133:2834-42. 2013
    ..7-33.5) in the whole series. In conclusion, the simplified BRCA2 classifier based on the co-occurrence of LOH at 13q13 and 14q32 could provide an indication to test for BRCA2 mutation in patients with ER-positive IDC. ..
  29. ncbi request reprint X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors
    Anne Vincent-Salomon
    Institut Curie, Centre de Recherche, Paris, France
    Cancer Res 67:5134-40. 2007
    ..Finally, we also show the necessity for combined global and single-cell approaches in the assessment of tumors with such a high degree of heterogeneity...
  30. ncbi request reprint KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome
    Sandy Azoulay
    Department of Pathology, Institut Curie, Paris Cedex, France
    Mod Pathol 18:1623-31. 2005
    ..This highly specific immunophenotype could be useful to differentiate adenoid cystic carcinoma of the breast from other subtypes of breast carcinoma such as cribriform carcinoma...
  31. ncbi request reprint [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance]
    Veronique Dieras
    Departement d Oncologie Medicale, Institut Curie, 26, rue d Ulm, 75248 Paris Cedex 05
    Bull Cancer 94:259-66. 2007
    ..It would be interesting to identify the mechanisms of trastuzumab resistance in breast tumors in order to reverse or prevent it. The characterization of these mechanisms would also provide novel strategies for alternative treatments...
  32. pmc 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis
    Sylvie Rodrigues-Ferreira
    Institut Cochin, Universite Paris Descartes, INSERM U567, CNRS UMR8104, Paris, France
    PLoS ONE 4:e7239. 2009
    ..The present study investigates the expression and functional effects of MTUS1 gene products in breast cancer...
  33. doi request reprint Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum
    Marick Lae
    Service de Pathologie, Section Médicale, Institut Curie, Paris Cedex, France
    Mod Pathol 22:291-8. 2009
    ..These results support the hypothesis that secretory breast carcinomas have immunohistochemical and genetic features that distinguish them from other basal-like tumors of the breast...
  34. ncbi request reprint High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer
    Isabelle Peguillet
    Authors Affiliations Clinical immunology Laboratory Center of Clinical Investigations CICBT507 IGR Curie Departments of Pathology, and Medical Oncology and Inserm U932, Institut Curie, Paris, France
    Cancer Res 74:2204-16. 2014
    ..In summary, our results lend support to the hypothesis that CD4(+) T cells are involved in human antitumor responses...
  35. ncbi request reprint Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, Paris, France
    Eur J Cancer 40:1502-8. 2004
    ..The sequential analysis of MI in breast cancers treated by preoperative CT thus provides a surrogate for predicting long-term outcome...
  36. ncbi request reprint Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience
    Manuela Zanni
    Department of Clinical Hematology, Institut Curie, Paris, France
    Hematology 17:76-84. 2012
    ..This study shows that (18)FDG PET has a lower sensitivity than MRI to detect ophthalmologic lymphoma, particularly in non-conjunctival sites...
  37. pmc External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement
    David Hajage
    Department of Biostatistics, Institut Curie, Paris, France
    PLoS ONE 6:e27446. 2011
    ..We provide the validation of Adjuvant! Online algorithm on two breast cancer datasets, and we determined whether the accuracy of Adjuvant! Online is improved with other well-known prognostic factors...
  38. ncbi request reprint Stereotactic radioguided surgery by siteSelect for subclinical mammographic lesions
    Virginie Doridot
    Department of General and Breast Surgery, Institut Curie, 26 Rue d Ulm, 75006 Paris, France
    Ann Surg Oncol 12:181-8. 2005
    ..We defined the indications for and evaluated the results of a new technique for radioguided surgery, the SiteSelect system. The procedure allows en-bloc resection of the breast parenchyma under local anesthesia...
  39. doi request reprint Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Clin Exp Metastasis 25:871-5. 2008
    ..Dissemination of DTC in other host organ and/or epithelial-mesenchymal transition from cytokeratin-positive to cytokeratin-negative DTC may explain this observation...
  40. ncbi request reprint Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix
    Christophe Rosty
    Departement de Pathologie, Institut Curie, Section Médicale, Paris, France
    Int J Gynecol Pathol 23:13-7. 2004
    ..Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients...
  41. ncbi request reprint Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage
    Amélie Monteau
    Department of Radiation Oncology, Institut Curie, Paris, France
    Int J Radiat Oncol Biol Phys 75:1021-8. 2009
    ..Following breast-conserving surgery for DCIS, reexcision before radiotherapy is recommended when margins are close or involved. We investigated whether an additional radiation dose could replace reexcision...
  42. ncbi request reprint Phyllodes tumors of the breast segregate in two groups according to genetic criteria
    Marick Lae
    Departement de Biologie des Tumeurs, Service de Pathologie, Institut Curie Hôpital, Paris, France
    Mod Pathol 20:435-44. 2007
    ..Helpful additional pathological criteria for differentiating the two genetic groups of phyllodes tumors are the nuclear size and the mitotic rate...
  43. pmc Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 7:e47390. 2012
    ....
  44. doi request reprint Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer
    Virginie Maire
    Institut Curie, Centre de Recherche, Paris, France
    Cancer Res 73:813-23. 2013
    ..Altogether, our observations suggest PLK1 inhibition as an attractive therapeutic approach, in association with conventional chemotherapy, for the management of patients with TNBC...
  45. pmc Molecular profiling of patient-derived breast cancer xenografts
    Fabien Reyal
    Translational Research Department, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Breast Cancer Res 14:R11. 2012
    ..In this work, we analyzed the genomic and gene expression profiles of human BC xenografts and the corresponding patient tumors...
  46. doi request reprint Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation
    Tatiana Popova
    Centre de Recherche, University Paris Descartes, Paris, France
    Cancer Res 72:5454-62. 2012
    ..This assay may ease the challenge of selecting patients for genetic testing or recruitment to clinical trials of novel emerging therapies that target DNA repair deficiencies in cancer...
  47. ncbi request reprint Tumor antigens and antigen-presenting capacity in breast cancer
    Raymond S McDermott
    Departement d Oncologie Medicale, Institut Curie, Paris, France
    Pathobiology 70:324-32. 2002
    ..We screened for dendritic cell infiltration, tumor MHC II expression and associated lymphocytic reaction in the context of three established breast tumor antigens...
  48. ncbi request reprint [Lobular neoplasia]
    Brigitte Sigal-Zafrani
    Institut Curie, 26 Rue d Ulm, 75005 Paris
    Ann Pathol 23:547-53. 2003
    ..Mass screening is challenging the current opinion that lobular disease cannot be detected by mammography. This raises the problem of the optimal management of patients with lobular neoplasia on needle core biopsies...
  49. pmc Oxidative stress promotes myofibroblast differentiation and tumour spreading
    Aurore Toullec
    Laboratory of Stress and Cancer, INSERM U830, Institut Curie, 75248 Paris Cedex 05, France
    EMBO Mol Med 2:211-30. 2010
    ..Collectively, our data uncover a new mechanism by which oxidative stress increases the migratory properties of stromal fibroblasts, which in turn potentiate tumour dissemination...
  50. pmc Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
    Bérengère Marty
    Département de Transfert, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Breast Cancer Res 10:R101. 2008
    ..In contrast to HER2+ carcinomas, no targeted therapy is currently available for the treatment of patients with BLCs. In order to discover potential therapeutic targets, we aimed to discover deregulated signalling pathways in human BLCs...
  51. pmc Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance
    Valerie Choesmel
    UMR144 CNRS, Research Division, Institut Curie, Paris, France
    Breast Cancer Res 6:R556-70. 2004
    ..In the present study, we have assessed the clinical relevance of current methods aimed at detecting rare disseminated carcinoma cells...
  52. ncbi request reprint Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors
    Patricia Validire
    Department of Clinical Hematology, Institut Curie, Paris, France
    Am J Hematol 84:133-9. 2009
    ..These results suggest a specific management of NHL with breast involvement...
  53. ncbi request reprint Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice
    Paul Freneaux
    Department of Pathology, Institut Curie, Paris, France
    Mod Pathol 15:641-6. 2002
    ..The clinical significance of occult metastases in SN needs to be specified by long-term follow-up analysis...
  54. ncbi request reprint Nuclear FGF-2 facilitates cell survival in vitro and during establishment of metastases
    Rachel J Thomas-Mudge
    UMR144 CNRS, Institut Curie, Research Division, 26 Rue d Ulm, 75248 Paris 05, France
    Oncogene 23:4771-9. 2004
    ..This study provides both in vitro and in vivo evidence that the role of the nuclear 24 kDa FGF-2 isoform in carcinoma is the promotion of cell survival, thereby defining its association with poor prognosis in some human carcinomas...
  55. ncbi request reprint Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors
    Jérôme Meunier
    Department of Clinical Hematology, Institut Curie, France
    Hematol Oncol 22:143-58. 2004
    ..In conclusion, with a median follow-up of 7.5 years, our large cohort of patients represents one of the largest published series on primary ophthalmologic and intraocular malignant lymphoma...
  56. doi request reprint Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial
    Jean Yves Pierga
    Institut Curie, Paris, France
    Clin Cancer Res 14:7004-10. 2008
    ....
  57. ncbi request reprint [Routine sentinel node detection in breast cancer. Experience of the Curie Institute]
    Sophie Delahaye
    Service de chirurgie générale à orientation sénologique, Institut Curie, 26, rue d Ulm, 75005 Paris, France
    Bull Cancer 91:641-7. 2004
    ..This article is an evaluation of the sentinel lymph node technique in a specialized Center providing a breakdown of the strong points and weak points of the procedure...
  58. ncbi request reprint Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature
    Yohann Loriot
    Department of Clinical Hematology, Institut Curie, France
    Leuk Lymphoma 47:1023-8. 2006
    ..Patients with lymphoma and melanoma should be closely monitored to detect the appearance of a second malignancy. Further studies are therefore warranted to elucidate this peculiar association...
  59. ncbi request reprint HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, Paris, France
    Cancer 94:2169-73. 2002
    ..The objective of this study was to determine whether HER2 expression levels in breast carcinomas were modified by chemotherapy or during the metastatic process...
  60. ncbi request reprint Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas
    Fabien Reyal
    Unite Mixte de Recherche 144, Centre National de la Recherche Scientifique, Paris, France
    Cancer Res 65:1376-83. 2005
    ..Transcription correlation maps are a new way of visualizing transcriptome data. They will help to identify new genes involved in tumor progression and new mechanisms of gene regulation in tumors...
  61. ncbi request reprint Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options
    Didier Decaudin
    Service d Hematologie, Institut Curie, 26 Rue d Ulm, 75 248 Paris cedex 05, France
    Blood 108:1451-60. 2006
    ..The aims of this review are to present the current knowledge on the biology of these lymphomas, their clinical features and prognostic factors, and the panel of all available treatment options...
  62. ncbi request reprint Ocular adnexal lymphoma and Helicobacter pylori gastric infection
    Didier Decaudin
    Department of Clinical Hematology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Hematol 85:645-9. 2010
    ..This suggests a novel mechanism of indirect infection-associated lymphomagenesis whereby chronic local antigen stimulation would lead to the emergence of ectopic B-cell lymphoma...
  63. pmc A "class action" against the microenvironment: do cancer cells cooperate in metastasis?
    François Clément Bidard
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Cancer Metastasis Rev 27:5-10. 2008
    ..As a result, after completion of the metastatic process, the series of microenvironmental changes from the primary tumor to the metastatic site may promote colonization of metastases by nonmetastatic cancer cells of the primary tumor...
  64. ncbi request reprint Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients
    Patricia De Cremoux
    Departement de Biologie des Tumeurs, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex, France
    Anticancer Res 29:1475-82. 2009
    ..This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients...
  65. ncbi request reprint Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia
    Emilie Le Toriellec
    Institut Curie, Centre de Recherche, Paris
    Blood 111:2321-8. 2008
    ..The second Cdkn1b allele was maintained and expressed in these preleukemic clones. Altogether, these data strongly implicate CDKN1B haploinsufficiency in the pathogenesis of T-PLL...
  66. ncbi request reprint Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?
    Didier Decaudin
    Department of Clinical Hematology, Institut Curie, Paris, France
    Anticancer Drugs 19:761-5. 2008
    ..psittaci antibodies. This paper also provides some methodological suggestions for future studies in the field of chlamydia-lymphoma associations...
  67. pmc The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling
    Cristovão Moreira Sousa
    Institut Curie, Paris, France CNRS UMR 3306, Orsay, France
    EMBO Mol Med 5:309-25. 2013
    ..This leads to its accumulation and to subsequent increases in cell motility and proliferation. Our study may thus have important implications for both cancer and HD...
  68. ncbi request reprint Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors
    Nathalie T Joncker
    Laboratoire d Immunologie, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Int J Cancer 118:1205-14. 2006
    ..These results suggest that to find activated effector T cells in a tissue does not always mean that a specific immune response is taking place...
  69. doi request reprint High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors
    Elodie Manie
    Institut Curie, Centre de Recherche, Paris, France
    Cancer Res 69:663-71. 2009
    ..In conclusion, TP53 mutation is highly recurrent in BLCs independently of BRCA1 status, but not a common feature of BRCA1 luminal tumors...
  70. ncbi request reprint [Targeting epidermal growth factor receptor in cancer of the breast]
    Veronique Dieras
    Departement d Oncologie Medicale, Institut Curie, 26, rue d Ulm, 75005 Paris
    Bull Cancer 90:S257-62. 2003
    ..However the complexity of erbB network requires the targeting of multiple molecular sites within the network and the characterization of tumor profiles in order to optimally select patients for these therapies...
  71. doi request reprint [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 58, rue Montalembert, 63011 Clermont Ferrand, France
    Ann Pathol 30:357-73. 2010
    ..Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs)...
  72. doi request reprint Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial
    Christophe Le Tourneau
    Institut Curie, Paris, France
    Target Oncol 7:253-65. 2012
    ..Finally, we will discuss the multiple challenges associated with the implementation of personalized medicine in oncology, as well as perspectives for the future...
  73. pmc Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development
    Anne Vincent-Salomon
    Medical Division, Department of Tumor Biology, Institut Curie, Paris, France
    Breast Cancer Res 5:101-6. 2003
    ..DNA profiling technology is also being applied to uncover pathways that lead to a metastatic phenotype...
  74. ncbi request reprint Consecutive conjunctival melanoma and extranodal marginal zone B-cell lymphoma of MALT type in an adult patient
    Livia Lumbroso-Le Rouic
    Service d Ophtalmologie, Institut Curie, Paris, France
    Arch Ophthalmol 123:397-9. 2005
  75. ncbi request reprint Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes
    Roman Rouzier
    Department of Surgery, Institut Curie, Paris, France
    J Clin Oncol 20:1304-10. 2002
    ..To determine the incidence and prognostic significance of eradication of cytologically proven axillary lymph node metastases in breast cancer patients treated with primary chemotherapy...
  76. ncbi request reprint Re: HER2 testing in the real world
    Anne Vincent-Salomon
    J Natl Cancer Inst 95:628; author reply 628-9. 2003
  77. ncbi request reprint Columnar cell lesions of the breast
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, U S A
    Adv Anat Pathol 10:113-24. 2003
    ..Recent studies have begun to provide insights into the biological nature and clinical significance of these lesions. In this article, we review the current state of knowledge and propose a simplified scheme for their classification...
  78. doi request reprint ESR1 gene amplification in breast cancer: a common phenomenon?
    Anne Vincent-Salomon
    Nat Genet 40:809; author reply 810-2. 2008
  79. ncbi request reprint Re: Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas
    Patricia De Cremoux
    J Natl Cancer Inst 98:365-6. 2006
  80. ncbi request reprint A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
    ..We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis...
  81. pmc Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-up
    Isabelle de Mascarel
    Department of Pathology, Institut Bergonie, Regional Cancer Center, Bordeaux, France
    Virchows Arch 451:1-10. 2007
    ..Epithelial atypia could be more a risk marker of concomitant than subsequent cancer...
  82. ncbi request reprint A new model of patient tumor-derived breast cancer xenografts for preclinical assays
    Elisabetta Marangoni
    U612 Institut National de la Sante et de la Recherche Medicale, Pharmacologie Préclinique Antitumorale, Paris Anatomie et Cytologie Pathologique, Hopital Trousseau, Tours, France
    Clin Cancer Res 13:3989-98. 2007
    ..To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays...
  83. ncbi request reprint [HER2 gene amplification assay: is CISH an alternative to FISH?]
    Yves Denoux
    Service d Anatomie Pathologique, Centre Francois Baclesse, 14076 Caen Cedex 5
    Ann Pathol 23:617-22. 2003
    ..We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining...
  84. ncbi request reprint [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:555-63. 2003
    ..The evaluation of the post treatment tumor residue helps in determinating tumor response to treatment, establishing prognosis and adjusting adjuvant regimens. Standard histopathological procedures are mandatory...
  85. ncbi request reprint Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma
    Gonzague De Pinieux
    Service d Anatomie Pathologique, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75679, Paris Cedex 14, France
    Virchows Arch 444:415-9. 2004
    ..Patients with urothelial carcinomas overexpressing HER-2/ neu using IHC are potential candidates for targeted chemotherapy...
  86. pmc HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients
    Marianne Tuefferd
    JE2492, Universite Paris Sud, IFR69, Villejuif, France
    PLoS ONE 2:e1138. 2007
    ....
  87. ncbi request reprint High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study
    Magali Lacroix-Triki
    Department of Pathology, Institut Claudius Regaud, 20 24 rue du Pont saint Pierre, 31052 Toulouse Cedex, France
    Eur J Cancer 42:2946-53. 2006
    ..82). As expected, the score 2+ group showed poor agreement (kappa=0.38). A quality assurance process showed that ring studies and adherence to national guidelines greatly improve inter-observer reproducibility...
  88. ncbi request reprint Skin lymphomatous lesions treated by rituximab: a necrotic life-threatening evolution
    Lionel Vedrine
    Leuk Lymphoma 45:1717-8. 2004